Nicolaes GA, Dahlbäck B (februarie 2003). „Congenital and acquired activated protein C resistance”. Seminars in Vascular Medicine. 3 (1): 33–46. doi:10.1055/s-2003-38331. PMID15199491.
Kisiel W, Ericsson LH, Davie EW (noiembrie 1976). „Proteolytic activation of protein C from bovine plasma”. Biochemistry. 15 (22): 4893–900. doi:10.1021/bi00667a022. PMID990250.
Mosnier LO, Griffin JH (). „Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities”. Frontiers in Bioscience. 11: 2381–99. doi:10.2741/1977. PMID16720321.
Kisiel W, Canfield WM, Ericsson LH, Davie EW (decembrie 1977). „Anticoagulant properties of bovine plasma protein C following activation by thrombin”. Biochemistry. 16 (26): 5824–31. doi:10.1021/bi00645a029. PMID588557.
Vehar GA, Davie EW (februarie 1980). „Preparation and properties of bovine factor VIII (antihemophilic factor)”. Biochemistry. 19 (3): 401–10. doi:10.1021/bi00544a001. PMID7356933.
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (mai 1994). „Mutation in blood coagulation factor V associated with resistance to activated protein C”. Nature. 369 (6475): 64–7. doi:10.1038/369064a0. PMID8164741.
PROWESS: recombinant Human Activated PROtein C Worldwide Evaluation in Severe Sepsis; Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ (martie 2001). „Efficacy and safety of recombinant human activated protein C for severe sepsis”. The New England Journal of Medicine. 344 (10): 699–709. doi:10.1056/NEJM200103083441001. PMID11236773.
Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W (iunie 2002). „Activation of endothelial cell protease activated receptor 1 by the protein C pathway”. Science. 296 (5574): 1880–2. doi:10.1126/science.1071699. PMID12052963.
Wildhagen KC, Lutgens E, Loubele ST, ten Cate H, Nicolaes GA (decembrie 2011). „The structure-function relationship of activated protein C. Lessons from natural and engineered mutations”. Thrombosis and Haemostasis. 106 (6): 1034–45. doi:10.1160/TH11-08-0522. PMID22072231.
Gu JM, Crawley JT, Ferrell G, Zhang F, Li W, Esmon NL, Esmon CT (noiembrie 2002). „Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality”. The Journal of Biological Chemistry. 277 (45): 43335–43. doi:10.1074/jbc.M207538200. PMID12218060.
España F, Berrettini M, Griffin JH (august 1989). „Purification and characterization of plasma protein C inhibitor”. Thrombosis Research. 55 (3): 369–84. doi:10.1016/0049-3848(89)90069-8. PMID2551064.
Nicolaes GA, Tans G, Thomassen MC, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J (septembrie 1995). „Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C”. The Journal of Biological Chemistry. 270 (36): 21158–66. doi:10.1074/jbc.270.36.21158. PMID7673148.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (iunie 2008). „Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)”. Chest. 133 (6 Suppl): 160S–198S. doi:10.1378/chest.08-0670. PMID18574265.
Kylat, Ranjit; Ohlsson, Arne (). „Recombinant human activated protein C for severe sepsis in neonates”. Cochrane Database of Systematic Reviews (4): CD005385. doi:10.1002/14651858.CD005385.pub3.
Nicolaes GA, Dahlbäck B (februarie 2003). „Congenital and acquired activated protein C resistance”. Seminars in Vascular Medicine. 3 (1): 33–46. doi:10.1055/s-2003-38331. PMID15199491.
Mammen EF, Thomas WR, Seegers WH (decembrie 1960). „Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II or autoprothrombin II-A)”. Thrombosis et Diathesis Haemorrhagica. 5: 218–49. PMID13765990.
Stenflo J (ianuarie 1976). „A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization”. The Journal of Biological Chemistry. 251 (2): 355–63. PMID1245477.
Kisiel W, Ericsson LH, Davie EW (noiembrie 1976). „Proteolytic activation of protein C from bovine plasma”. Biochemistry. 15 (22): 4893–900. doi:10.1021/bi00667a022. PMID990250.
Mosnier LO, Griffin JH (). „Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities”. Frontiers in Bioscience. 11: 2381–99. doi:10.2741/1977. PMID16720321.
Kisiel W, Canfield WM, Ericsson LH, Davie EW (decembrie 1977). „Anticoagulant properties of bovine plasma protein C following activation by thrombin”. Biochemistry. 16 (26): 5824–31. doi:10.1021/bi00645a029. PMID588557.
Vehar GA, Davie EW (februarie 1980). „Preparation and properties of bovine factor VIII (antihemophilic factor)”. Biochemistry. 19 (3): 401–10. doi:10.1021/bi00544a001. PMID7356933.
Walker FJ (iunie 1980). „Regulation of activated protein C by a new protein. A possible function for bovine protein S”. The Journal of Biological Chemistry. 255 (12): 5521–4. PMID6892911.
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (mai 1994). „Mutation in blood coagulation factor V associated with resistance to activated protein C”. Nature. 369 (6475): 64–7. doi:10.1038/369064a0. PMID8164741.
PROWESS: recombinant Human Activated PROtein C Worldwide Evaluation in Severe Sepsis; Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ (martie 2001). „Efficacy and safety of recombinant human activated protein C for severe sepsis”. The New England Journal of Medicine. 344 (10): 699–709. doi:10.1056/NEJM200103083441001. PMID11236773.
Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W (iunie 2002). „Activation of endothelial cell protease activated receptor 1 by the protein C pathway”. Science. 296 (5574): 1880–2. doi:10.1126/science.1071699. PMID12052963.
Wildhagen KC, Lutgens E, Loubele ST, ten Cate H, Nicolaes GA (decembrie 2011). „The structure-function relationship of activated protein C. Lessons from natural and engineered mutations”. Thrombosis and Haemostasis. 106 (6): 1034–45. doi:10.1160/TH11-08-0522. PMID22072231.
Gu JM, Crawley JT, Ferrell G, Zhang F, Li W, Esmon NL, Esmon CT (noiembrie 2002). „Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality”. The Journal of Biological Chemistry. 277 (45): 43335–43. doi:10.1074/jbc.M207538200. PMID12218060.
España F, Berrettini M, Griffin JH (august 1989). „Purification and characterization of plasma protein C inhibitor”. Thrombosis Research. 55 (3): 369–84. doi:10.1016/0049-3848(89)90069-8. PMID2551064.
Nicolaes GA, Tans G, Thomassen MC, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J (septembrie 1995). „Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C”. The Journal of Biological Chemistry. 270 (36): 21158–66. doi:10.1074/jbc.270.36.21158. PMID7673148.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (iunie 2008). „Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)”. Chest. 133 (6 Suppl): 160S–198S. doi:10.1378/chest.08-0670. PMID18574265.